BUZZ-Oncolytics Biotech jumps after pancreatic cancer therapy gets regulatory nod
ReutersJan 15, 2025 1:05 PM
U.S.-listed shares of Oncolytics Biotech ONC.TO, ONCY.O rise 35.8% to $1.10 premarket
ONCY says its pancreatic cancer therapy, pelareorep, has received regulatory approval to continue patient enrollment
ONCY is evaluating pelareorep in combination with chemotherapy regimen Folfirinox and immunotherapy atezolizumab
ONCY says it will move forward with full enrollment of 30 newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients in the first stage
All 5 brokerages covering the stock rate it "buy"
ONCY fell ~31% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
Why Ripple ETFs are Winning the Capital War Against Bitcoin
While Bitcoin and Ethereum ETFs face massive outflows, XRP ETFs have defied market trends with a historic 30-day inflow streak reaching $1.37 billion. Explore why institutional "smart money" is rotating into Ripple, the structural impact of the "Liquidity Lock," and why analysts set a 2026 price tarTradingKey
Tue, Feb 3
